Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome
| Autor: | Lisa Devlin, John David Moore Edgar, Hiba M. Shendi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
musculoskeletal diseases
Adolescent Antibodies Monoclonal Humanized Receptors Tumor Necrosis Factor Etanercept chemistry.chemical_compound Tocilizumab Rheumatology medicine Humans Treatment Failure Interleukin 6 Anakinra biology business.industry Interleukin-6 Mevalonate kinase medicine.disease Blockade Interleukin 1 Receptor Antagonist Protein Treatment Outcome chemistry Immunoglobulin G Monoclonal Immunology biology.protein Female Mevalonate Kinase Deficiency Periodic fever syndrome business Colchicine medicine.drug |
| Zdroj: | Journal of clinical rheumatology : practical reports on rheumaticmusculoskeletal diseases. 20(2) |
| ISSN: | 1536-7355 |
| Popis: | Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, autoinflammatory condition caused by mutations in the mevalonate kinase gene. There is no standard treatment for HIDS, and randomized controlled trials are lacking. Corticosteroids, colchicine, nonsteroidal anti-inflammatory drugs, statins, and cyclosporine are of limited efficacy in controlling this condition. Recent case reports suggest that most patients respond to etanercept or anakinra. Interleukin 6 blockade in HIDS has not been described. We report the case of a 13-year-old girl with HIDS, who failed to respond to colchicine, corticosteroids, etanercept, and anakinra but was successfully treated with the anti-IL-6 monoclonal antibody, tocilizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|